Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy by Palli, D et al.
BioMed CentralBMC Cancer
ssOpen AcceResearch article
Association between the BRCA2 N372H variant and male breast 
cancer risk: a population-based case-control study in Tuscany, 
Central Italy
Domenico Palli1, Mario Falchetti2, Giovanna Masala1, Ramona Lupi2, 
Francesco Sera1, Calogero Saieva1, Cristina D'Amico2, Marco Ceroti1, 
Piera Rizzolo2, Maria Adelaide Caligo3, Ines Zanna1 and Laura Ottini*2
Address: 1Molecular and Nutritional Epidemiology Unit, CSPO, Scientific Institute of Tuscany, 50139 Florence, Italy, 2Department of Experimental 
Medicine, University of Rome "La Sapienza", 00161 Rome, Italy and 3Division of Surgical, Molecular and Ultrastructural Pathology, Department 
of Oncology, University of Pisa and Pisa University Hospital, 56126 Pisa, Italy
Email: Domenico Palli - d.palli@cspo.it; Mario Falchetti - mario.falchetti@uniroma1.it; Giovanna Masala - g.masala@cspo.it; 
Ramona Lupi - ramona.lupi@uniroma1.it; Francesco Sera - f.sera@cspo.it; Calogero Saieva - c.saieva@cspo.it; 
Cristina D'Amico - cdamico@supereva.it; Marco Ceroti - m.ceroti@cspo.it; Piera Rizzolo - pierarizzolo@yahoo.it; 
Maria Adelaide Caligo - m.caligo@med.unipi.it; Ines Zanna - i.zanna@cspo.it; Laura Ottini* - laura.ottini@uniroma1.it
* Corresponding author    
Abstract
Background: Male breast cancer (MBC) is a rare disease and little is known about its aetiology. Germ-
line mutations of BRCA2 and, at lower frequency, of BRCA1 are implicated in a relatively small proportion
of MBC cases. Common polymorphic variants in BRCA1 and BRCA2 genes may represent breast cancer
(BC) susceptibility alleles and could be associated with a modestly increased risk of MBC at population
level. Considering the relevant role of BRCA2 in MBC, we investigated whether the BRCA2 N372H variant,
representing the only common non-synonymous polymorphism in BRCA2, might modulate the risk of BC
in male populations.
Methods: A case-control study was performed comparing a population-based series of 99 MBC cases,
characterized for BRCA1 and BRCA2 mutations, with 261 male population controls, all residing in Tuscany,
Central Italy. All MBC cases and controls were genotyped for the BRCA2 N372H allele by TaqMan allelic
discrimination assays. To evaluate the genotype specific risk of the BRCA2 N372H variant, MBC carriers
of germ-line BRCA1/2 mutations were excluded from the analyses.
Results: No association emerged in univariate and age-adjusted analyses. Age-specific analyses suggested
an increased risk for the HH homozygous genotype in subjects younger than 60 years. A statistically
significant interaction emerged between this genotype and age (p = 0.032). When analyses were restricted
to MBC cases enrolled in the first 4 years following diagnosis, a recessive model showed a significantly
increased risk of MBC in HH subjects younger than 60 years (OR = 5.63; 95% CI = 1.70;18.61).
Conclusion: Overall, our findings, although based on a relatively small series, suggest that the BRCA2 HH
homozygous genotype might be positively associated with an increased risk of MBC in men younger than
60 years.
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Male breast cancer (MBC) is a rare disease and little is
known about its aetiology compared with female breast
cancer (FBC). MBC represents less than 1% of all cancers
in men and its incidence is increasing in younger men [1].
In Italy, MBC accounts for 0.2% of all cancers in males [2].
Similar to FBC, a positive family history (FH) of breast
cancer (BC) is associated with increased risk of MBC and
approximately 15% to 20% of male patients with BC have
a positive FH [3]. The two major hereditary BC genes,
BRCA1 (OMIM #113705) and, to a larger extent, BRCA2
(OMIM # 600185), are implicated in MBC. Both genes are
estimated to be responsible respectively for up to 16% and
76% of the MBCs in high-risk breast/ovarian cancer fami-
lies [3,4]. The frequencies of BRCA1/BRCA2 mutations are
sharply different in ethnically diverse population- and
clinic-based series ranging from 0% to 4% for BRCA1 and
from 4% to 40% for BRCA2 [5,6]. However, at population
level only a small proportion of all MBC cases are due to
inherited mutations in BRCA1/BRCA2 genes.
Low-penetrance polymorphisms in BC susceptibility
genes are present in a high percentage of individuals and
might account for BC risk at population level. In this
respect, common polymorphic variants in BRCA1/BRCA2
genes may represent BC susceptibility alleles and could be
associated with a modest risk of MBC that would explain,
on population basis, a large proportion of the disease.
The N372H (rs144848) polymorphism is the unique var-
iant in BRCA2 gene that results in an amino acid change
and has a rare allele frequency greater than 10%. Little is
known on the functional effect of this polymorphism,
although the substitution of asparagine (a neutral amino
acid) by histidine (a basic amino acid) may be expected to
affect BRCA2 structure and function as it falls in a region
that has been shown to interact with the histone acetyl-
transferase P/CAF prior to transcriptional activation of
other genes [7]. Intriguingly, an excess of NH heterozy-
gotes was observed in female controls and an effect of this
variant on fetal survival in a sex-dependent manner has
been suggested as newborn females showed an excess of
heterozygotes and a deficit of homozygotes, whereas the
opposite was observed in newborn males [8].
Several studies have analysed the effect of the BRCA2
N372Hpolymorphism on the risk of breast cancer in
female populations with inconsistent findings. The HH
homozygous genotype was reported to be associated with
a 1.3- to 1.5-fold increased risk of breast and ovarian can-
cer [8-11]. In contrast, other studies did not show any
effect of this polymorphism on breast or ovarian cancer
risk [12-15]. A recent large pooled analysis, however,
could not exclude an effect of this genotype in younger
women [16]. To our knowledge, the effect of the BRCA2
N372H polymorphism on BC risk has not yet been inves-
tigated in male populations.
Considering the relevance of BRCA2 in MBC, we have per-
formed a population-based case-control study to investi-
gate the role of BRCA2 N372H variant on BC risk in men,
comparing a series of MBC, characterized for BRCA1 and
BRCA2 mutation status, with a control group from the
same area of Central Italy (Florence, Tuscany).
Methods
Study population and data collection
In a previous study [17], we had identified a population-
based series of 25 MBC cases diagnosed in the area of Flor-
ence (Tuscany, Central Italy) during the period 1990–
1998. One of the problems in MBC studies is represented
by the rarity of the disease: in order to increase the
number of cases for meaningful statistical analyses it is
necessary to enrol patients diagnosed over a long period
of time (or in a larger geographical area). Thus, using all
available local sources (including Pathology Departments
and the Hospital Discharge database) the original series
has been expanded and 74 additional MBC cases diag-
nosed in the period 1991–2006 have been enrolled for a
total of 99 MBCs available for this study, all residing in
Tuscany.
Overall, after exclusion of deceased and migrated patients,
85 additional unrelated MBC were traced and invited to
participate into the study. Eleven cases refused to partici-
pate, mostly because of advanced age or severe illness.
Confirming our previous response rate of about 80%, 74
of these 85 MBC cases (87.1%) agreed to participate.
According to the original study protocol, each MBC
patient provided: 1) informed consent; 2) blood samples;
3) detailed information on his personal and family his-
tory of cancer at any site, including all first- and second-
degree relatives of both genders; 4) a detailed smoking
and working history up to the date of BC diagnosis. Infor-
mation has been validated by available sources (mainly
local Cancer and Mortality Registries). Procedures to
maintain confidentiality for all the information collected
have been developed and strictly applied. The study was
approved by the local Ethical Research Committee (Flor-
ence Health Unit).
Population controls
In the frame of a multi-site epidemiological project, two
series of healthy adults of both sexes have been randomly
selected from the municipality lists of two areas in Tus-
cany: the city of Florence and one rural area [18,19]. All
participants signed an informed consent form and pro-
vided a blood sample. Out of 700 randomly selected sub-
jects, 553 subjects (79%) accepted to participate into thePage 2 of 7
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were available for analyses (eight of the initial 269 con-
trol's samples (3%) yielded insufficient DNA). The blood
samples have been processed at the study laboratory
(CSPO, Florence), in the same day of collection and
divided in specific aliquots (RBC, buffy coat, serum,
plasma). The aliquots have been stored in a -80°C freezer
at the Biological Bank of the Molecular Epidemiology
Unit at CSPO.
Mutational analysis
Buffy coat aliquots from MBC cases and controls were
anonymously shipped to the research laboratory (Experi-
mental Medicine, Rome) where genomic DNA was
extracted using QIAamp DNA Mini Kit (Qiagen Inc.,
Charlesworth, CA). The entire BRCA1 and BRCA2 coding
sequences, including intron-exon boundaries, were ana-
lysed by using single strand conformation polymor-
phisms (SSCP) combined with protein truncation test
(PTT) and automatic sequencing analysis [17,20]. Muta-
tions were always verified by PCR direct sequencing on
two independent blood samples (reference sequence for
BRCA1: Genbank, U14680; reference sequence for
BRCA2: Genbank, NM_000059).
SNP genotyping
The BRCA2 N372H (rs144848) polymorphism was ana-
lysed by TaqMan allelic discrimination using Real-Time
PCR. Fluorescent hybridisation probes, labelled with 6-
carboxyfluorescin (FAM) to detect the 1342C (372H)
allele and with Texas Red to detect the 1342A (372N)
allele were specifically designed. TaqMan assays were per-
formed in a reaction volume of 50 µl, comprising 100 ng
of DNA, 400 nM each probe, 400 nM each primer and 1 ×
Universal Master Mix (Biorad). The following conditions
were used for amplification: 3 minutes at 95°C and 55
cycles at 95°C for 10" and 63°C for 45". The Real-Time
PCR was accomplished on iCycler thermal cycler (Biorad)
with 96 × 0.2 ml samples. The fluorescence was visualised
through iCycler Optical System (Biorad) during Real-
Time PCR and analysed by using the iCycler IQ Real-Time
Detection System (Biorad) 3.0 software. About 15% of the
genotyping results were confirmed by sequencing analy-
sis. The genotype controls for the three possible genotypes
plus "no template" controls were always included in each
analysis.
Statistical analysis
Allele frequencies have been calculated as the number of
alleles divided by the number of chromosomes. Genotype
frequencies have been calculated as the number of partic-
ipants with a particular genotype divided by the number
of participants. Tests for Hardy-Weinberg equilibrium
among cases and controls have been assessed using Pear-
son's χ2 test with one degree of freedom comparing
expected genotype frequencies (based on observed qs) to
observed genotype frequencies. The association between
MBC risk and BRCA2 N372H was measured by the odds
ratio (OR) and its corresponding 95% confidence interval
and was estimated using unconditional logistic regression
after adjustment for age considered as dichotomous vari-
able (<60 years, >60 years). The analysis were performed
with four logistic regression models based on a co-domi-
nant, dominant, recessive and multiplicative codominant
effect (inheritance model). In the dominant model, both
the heterozygous variant and rare homozygous variant
were combined in a dummy variable. In the recessive
model, the variant was defined in a dummy variable as
only the rare homozygous genotype. In the co-dominant
model both rare homozygous and heterozygous variant
effects were estimated using two dummy variables while
in the multiplicative codominant model a dose-response
effect were tested on the variable counting the number of
copies of the H allele. Analyses have also been carried out
according to stratification by age at diagnosis for cases and
age at interview for controls (below/above 60 years) and
restricted to MBC cases with a time interval after diagnosis
shorter than the median value of the series (4 years). Inter-
actions between age, modelled as dichotomous variable
(<60 years, >60 years), and genotype under co-dominant,
dominant, recessive and multiplicative codominant mod-
els, were assessed using Likelihood Ratio test (LR) com-
paring logistic regression models with and without
interaction term.
Results
In order to evaluate the putative influence of the BRCA2
N372H polymorphism on MBC risk, we carried out a pop-
ulation-based case-control study based on a total of 99
MBC cases and 261 adult male controls from the same
area of Central Italy (Florence, Tuscany). The mean age at
interview was 67.9 (SD 11.8) in cases and 55.9 (SD 6.9)
in controls (p < 0.0001). The mean age at diagnosis in the
MBC series was 63.4 (SD 12.1; median 65) and the time
interval between diagnosis and interview ranged from 0 to
26 years (median 4.0). A detailed FH for breast and ovar-
ian cancers diagnosed in first-degree relatives was col-
lected for all MBC cases. Overall, 25.3% (25/99) of MBC
patients reported a first degree FH positive for breast/ovar-
ian cancer.
MBC cases were characterized for BRCA1 and BRCA2
mutations. Overall, 8/99 (8.1%) MBC cases resulted to be
mutated in BRCA1/BRCA2 genes: 6 cases (6.1%) carried
BRCA2 mutations and 2 cases (2.0%) carried BRCA1
mutations. All 99 MBC cases and 261 controls were ana-
lysed for the BRCA2 N372H allele and genotype frequen-
cies. Genotype distribution was consistent with Hardy-
Weinberg equilibrium (p = 0.529) among our population
controls and cases (p = 0.067). In order to evaluate thePage 3 of 7
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phism, MBC carriers of germ-line BRCA1/2 mutations (8
cases) were excluded from the analyses.
As shown in Table 1, no statistically significant difference
in the distribution of the three specific BRCA2 N372H
genotypes was observed between MBC cases and controls
(p = 0.46). The age-adjusted analysis of the genotype-spe-
cific risks showed that individuals with NH heterozygous
and HH homozygous genotypes were not at increased
MBC risk. These results were confirmed on dominant,
recessive and multiplicative codominant transmission
models (data not shown). Separate analyses stratified
according to age (below/above 60 years) showed a ten-
dency towards an inverse association between the H allele
and MBC risk in the older sub-group (age > 60 years),
although far from being statistically significant. On the
contrary, an increased MBC risk (OR = 3.12; 95%CI =
1.08; 9.03) was observed in younger subjects (age ≤ 60
years) on the basis of a recessive model (Table 2). A model
specifically aimed to evaluate a possible effect modifica-
tion of age on the association between MBC risk and the
HH homozygous genotype found a statistically significant
interaction (LR test p = 0.02; ORinteraction = 0.17; 95%CI =
0.04; 0.76).
We carried out additional analyses taking into account the
length of the interval between diagnosis and blood dona-
tion among cases. Overall, no association between the H
allele and MBC risk was observed, when analyses were
restricted to a comparison between the group of 53 MBC
cases with an interval shorter than the median value of the
whole series (≤4 years) and the series of controls (Table
3). Additional analyses stratified by age, showed a
strongly increased MBC risk (OR = 5.63; 95%CI = 1.70;
18.61) in younger subjects with the HH homozygous gen-
otype (Table 4), while no statistically significant result
emerged in older individuals. Further statistical analyses
confirmed that the effect of the HH homozygous geno-
type on MBC risk tended to be modified by age also in
these analyses restricted to MBC cases with a shorter time
interval between diagnosis and blood donation (LR test p
= 0.03; ORinteraction = 0.17 (95%CI = 0.04–0.83). Sensitiv-
ity analyses were carried out based on cut-off points for
both age at diagnosis and time interval after diagnosis dif-
ferent from those identified a priori. These analyses con-
firmed the association, when older individuals (up to 65
years of age) or cases with a longer time interval (up to 6
years) were included.
Discussion
We evaluated the effect of the BRCA2 N372H (1342A > C)
polymorphism on MBC risk in a population based case-
control study. Overall, a positive association between the
HH genotype and an increased risk of MBC was suggested
in men younger than 60 years; this association was partic-
ularly strong (with a five-fold increased risk) when analy-
ses were restricted to 53 MBC cases enrolled in the study
with a blood donation not later than 4 years after their
diagnosis. To our knowledge, the present study is the first
reporting an analysis of the association between BC risk
and the BRCA2 N372H variant in men.
The role of the BRCA2 N372H variant on BC risk has been
investigated by several studies in women from different
populations with inconsistent findings that might reflect
genetic differences across populations. In particular the
HH genotype was associated with a 1.3- to 1.5-fold
increased risk of BC in series from Northern Europe [8],
Australia [9] and in a selected series of radiologic technol-
ogists from USA [10]. This association was not detected in
series from Central Europe [13], Japan [12] and in an
unselected series from USA [14].
Here, we performed a population-based case control
study on male subjects all residing in the same area of
Central Italy (Tuscany). Our analyses based on a recessive
transmission model suggested an association between the
BRCA2 N372H variant and increased MBC risk in men
younger than 60 years. This effect on MBC risk was partic-
ularly evident when analyses were restricted to the sub-
group of MBC cases with an interval between diagnosis
and blood donation ≤ 4 years, in order to avoid a possible
selection bias related to the enrolment of MBC cases with
a longer survival in the attempt of expanding the series of
patients affected with this rare disease. Overall, we had
found a statistically significant interaction between
N372H genotype and age: the effect on MBC risk of the
Table 1: Distribution of 91 MBC cases not mutated in BRCA genes and 261 male population controls according to the BRCA2 N372H 
genotype frequencies.
Genotype Cases n % Controls n % Co-dominant model OR 95% CI
N/N 48 52.7 127 48.7
N/H 31 34.1 107 41.0 0.68 (0.40; 1.18)
H/H 12 13.2 27 10.3 0.94 (0.43; 2.09)
Total 91 100.0 261 100.0
Odds Ratios (OR) and 95% Confidence Intervals according to a co-dominant model, estimated by a logistic regression model after adjustment for 
age considered as a dichotomous variable (<60 years, >60 years).Page 4 of 7
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age. In this respect, it is noteworthy that a recent pooled
analysis with over 15,000 BC cases and 15,000 controls
provided some evidence of an interaction of BRCA2
N372H with age, suggesting a possibly increased BC risk
in women younger than 40 years of age [16].
It could be speculated that the effect of the BRCA2 N372H
variant on BC risk could be modulated by the interactions
with hormonal factors. In males, the hormonal back-
ground is not influenced by reproductive factors as in
females and sex steroid levels decline with age [21].
Intriguingly, an association of the BRCA2 N372H variant
with idiopathic male infertility, a condition possibly
Table 3: Distribution of 53 MBC cases with a time interval between diagnosis and interview ≤4 years and 261 male population controls 
according to the BRCA2 N372H genotype frequencies.
Genotype Cases n % Controls n % Co-dominant model 
OR 95% CI
N/N 24 45.2 127 48.7
N/H 18 34.0 107 41.0 0.79 (0.40; 1.58)
H/H 11 20.8 27 10.3 1.67 (0.70; 3.97)
Total 53 100.0 261 100.0
Odds Ratios (OR) and 95% Confidence Intervals according to a co-dominant model, estimated using logistic regression models after adjustment for 
age considered as a dichotomous variable (<60 years, >60 years).
Table 2: Distribution of 91 MBC cases not mutated in BRCA genes and 261 male population controls according to the BRCA2 N372H 
genotype frequencies, stratified by age at diagnosis.
Genotype Cases n % Controls n % Co-dominant 
model OR 95% CI
Recessive model 
OR 95% CI
≤60 years
N/N 16 50.0 94 54.0
N/H 10 31.2 68 39.1 0.86 (0.37; 2.03)
H/H 6 18.8 12 6.9 2.94 (0.94; 9.15) 3.12 (1.06; 9.16)
Total 32 100.0 174 100.0
>60 years
N/N 32 54.2 33 37.9
N/H 21 35.6 39 44.8 0.56 (0.27; 1.15)
H/H 6 10.2 15 17.2 0.41 (0.14; 1.22) 0.54 (0.20; 1.51)
Total 59 100.0 87 100.0
Odds Ratios (OR) and 95% Confidence Intervals according to co-dominant and recessive models, estimated using logistic regression models. 
Interaction among between BRCA2 N372H genotype and age: ORinteraction = 0.17 (95%CI = 0.04–0.76); p = 0.02.
Table 4: Distribution of 53 MBC with a time interval between diagnosis and interview ≤4 years and 261 male population controls 
according to the BRCA2 N372H genotype frequencies, stratified by age at diagnosis.
Genotype Cases n % Controls n % Co-dominant 
model OR 95% CI
Recessive model 
OR 95% CI
≤60 years
N/N 6 35.3 94 54.0
N/H 6 35.3 68 39.1 1.38 (0.43; 4.47)
H/H 5 29.4 12 6.9 6.53 (1.73; 24.69) 5.63 (1.70;18.61)
Total 17 100.0 174 100.0
>60 years
N/N 18 50.0 33 37.9
N/H 12 33.3 39 44.8 0.56 (0.24;1.34)
H/H 6 16.7 15 17.2 0.73 (0.24;2.22) 0.96 (0.34;2.71)
Total 36 100.0 87 100.0
Odds Ratios (OR) and 95% Confidence Intervals according to co-dominant and recessive models estimated using logistic regression models. 
Interaction between BRCA2 N372H genotype and age: ORinteraction = 0.17 (95%CI = 0.04–0.83); p = 0.03.Page 5 of 7
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recently suggested [22]. Here, we found that the BRCA2
N372H variant increased MBC risk in younger men that
may show higher steroid hormones levels.
On the other hand, MBC risk could be influenced by inter-
actions between genetic and environmental factors.
Recently, we reported a possible modifying effect on MBC
risk of an occupational exposure to chemicals, as polycy-
clic aromatic hydrocarbon, in subjects carrying BRCA1/2
germ-line mutations [23].
It has been also suggested that the BRCA2 N372H variant
might affect fetal survival in a sex-dependent manner. In
fact, an excess of NH heterozygotes in newborn females,
compared to newborn males, has been observed and the
BRCA2 N372H genotype distribution showed a signifi-
cant deviation from the Hardy-Weinberg equilibrium in
adult female controls with an excess of heterozygotes and
a deficit of both homozygotes [8]. In our male population
the overall distribution of the N372H genotypes fitted the
Hardy-Weinberg equilibrium and the genotype frequen-
cies were similar to those recently reported for a male pop-
ulation from UK [24] and for female populations from
Central Europe and USA [13,14].
Conclusion
Overall, our findings, although based on a relatively small
series, suggest that the HH homozygous genotype might
be positively associated with an increased risk of MBC in
men younger than 60 years. This effect appears to be mod-
ified by age, with a statistically significant interaction. Due
to the rarity of MBC, larger collaborative studies are
needed to confirm our results in different male popula-
tions.
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